文献速递眼底病与葡萄膜炎

脉络膜痣生长风险因素与恶性转化相关吗?基于经验证基因组生物标志物的评估

Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.
PubMed 文献 · Am J Ophthalmol · 2018-09-07

该研究对207例厚度<3.5 mm的脉络膜黑色素细胞肿瘤行细针活检,以基因表达谱class 2作为恶性转化的验证生物标志物。结果显示,仅患者年龄>60岁和肿瘤厚度>2.25 mm与class 2 profile相关,而 documented growth 及其他常用临床风险因素均不相关。因此,多数可疑脉络膜痣在治疗前观察生长仍是合理的。

要点

  • 年龄>60岁和厚度>2.25 mm与class 2 profile相关,OR分别为2.8和3.5。
  • 多数可疑脉络膜痣治疗前观察生长仍合理。

核心结论

  • 常用脉络膜痣生长风险因素及记录的生长本身均非class 2基因表达谱所定义恶性转化的特征性指标。
  • 患者年龄>60岁和肿瘤厚度>2.25 mm可能有助于识别更可能具有class 2 profile的小脉络膜黑色素细胞肿瘤。
  • 对多数可疑脉络膜痣,治疗前观察生长仍合理。

研究设计与样本

  • 对207例厚度<3.5 mm的脉络膜黑色素细胞肿瘤行细针活检,分配基因表达谱class 1或class 2。
  • 以class 2 profile作为恶性转化的验证生物标志物。
  • 收集患者年龄、性别、肿瘤直径和厚度、后缘距视盘距离及多种临床特征。

主要发现

  • 年龄>60岁者具有class 2 profile的OR为2.8(95%CI 1.3-5.9),厚度>2.25 mm者为3.5(95%CI 1.4-8.8)。
  • 无其他临床特征或特征组合与class 2 profile相关。

关键数值与推荐

  • 患者年龄>60岁:OR 2.8(95%CI 1.3-5.9)。
  • 肿瘤厚度>2.25 mm:OR 3.5(95%CI 1.4-8.8)。

临床怎么用

  • 对于可疑脉络膜痣,不应仅凭常用生长风险因素或记录的生长判断恶性转化。
  • 年龄>60岁和厚度>2.25 mm可提示小脉络膜黑色素细胞肿瘤更可能具有class 2 profile。
  • 多数可疑脉络膜痣在治疗前观察生长仍是合理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To test the hypothesis that widely used clinical risk factors for growth of choroidal nevi are associated with malignant transformation. METHODS: Fine needle biopsy for assignment of gene expression profile (class 1 or class 2) was performed in 207 choroidal melanocytic tumors < 3.5 mm in thickness. The class 2 profile was employed as a validated biomarker for malignant transformation. The following data were collected: patient age and sex, tumor diameter and thickness, distance of posterior tumor margin from the optic disc, and the presence or absence of serous retinal detachment, orange lipofuscin pigment, drusen, retinal pigment epithelial fibrosis, retinal pigment epithelial atrophy, visual symptoms, and documented tumor growth. RESULTS: Clinical features associated with the class 2 profile included patient age > 60 years and tumor thickness > 2.25 mm (Fisher exact test, P = .002 for both). Documented growth was not associated with the class 2 profile (P = .5). The odds ratio of a tumor having the class 2 profile was 2.8 (95% confidence interval 1.3-5.9) for patient age > 60 years and 3.5 (95% confidence interval 1.4-8.8) for tumor thickness > 2.25 mm. For patients with both risk factors, the "number needed to treat" to identify 1 patient with a class 2 tumor was 4.3 (P = .0002). No other clinical feature or combination of features was associated with the class 2 profile. CONCLUSIONS: None of the widely used choroidal nevus risk factors for tumor growth, nor documented growth itself, is pathognomonic of malignant transformation as defined by class 2 gene expression profile. Patient age and tumor thickness may be helpful for identifying small choroidal melanocytic tumors that are more likely to have the class 2 profile. Observation for growth prior to treatment continues to be reasonable for most patients with suspicious choroidal nevi. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Harbour JW, Paez-Escamilla M, Cai L, et al. Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker. Am J Ophthalmol. 2018. PMID: 30195895. doi:10.1016/j.ajo.2018.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。